KYORIN Pharmaceutical Co Ltd (4569) - Financial and Strategic SWOT Analysis Review

KYORIN Pharmaceutical Co Ltd (4569) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

KYORIN Pharmaceutical Co Ltd (Kyorin), formerly KYORIN Holdings Inc, manufactures, develops, and commercializes pharmaceuticals including new ethical drugs, generic drugs and over-the-counter (OTC) drugs. The company offers diagnostics, reagents, intermediates, industrial chemicals and other products. Kyorin markets its products under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. It also provides solutions to medical professionals in infection-related fields. The company operates its business through its subsidiaries KYORIN Rimedio Co Ltd and KYORIN Pharmaceutical Group Facilities Co Ltd in Japan. Kyorin is headquartered in Chiyoda-Ku, Japan.

KYORIN Pharmaceutical Co Ltd Key Recent Developments

Aug 14,2023: MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
KYORIN Pharmaceutical Co Ltd - Key Facts
KYORIN Pharmaceutical Co Ltd - Key Employees
KYORIN Pharmaceutical Co Ltd - Major Products and Services
KYORIN Pharmaceutical Co Ltd - History
KYORIN Pharmaceutical Co Ltd - Company Statement
KYORIN Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
KYORIN Pharmaceutical Co Ltd - Business Description
Product Category: Generic Drugs
Performance
Product Category: New Ethical Drugs (Japan)
Performance
Product Category: New Ethical Drugs (Overseas)
Performance
R&D Overview
KYORIN Pharmaceutical Co Ltd - Corporate Strategy
KYORIN Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
KYORIN Pharmaceutical Co Ltd - Strengths
KYORIN Pharmaceutical Co Ltd - Weaknesses
KYORIN Pharmaceutical Co Ltd - Opportunities
KYORIN Pharmaceutical Co Ltd - Threats
KYORIN Pharmaceutical Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
KYORIN Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 14, 2023: MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
KYORIN Pharmaceutical Co Ltd, Key Facts
KYORIN Pharmaceutical Co Ltd, Key Employees
KYORIN Pharmaceutical Co Ltd, Major Products and Services
KYORIN Pharmaceutical Co Ltd, History
KYORIN Pharmaceutical Co Ltd, Subsidiaries
KYORIN Pharmaceutical Co Ltd, Key Competitors
KYORIN Pharmaceutical Co Ltd, Ratios based on current share price
KYORIN Pharmaceutical Co Ltd, Annual Ratios
KYORIN Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
KYORIN Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
KYORIN Pharmaceutical Co Ltd, Interim Ratios
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
KYORIN Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
KYORIN Pharmaceutical Co Ltd, Performance Chart (2020 - 2024)
KYORIN Pharmaceutical Co Ltd, Ratio Charts
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
KYORIN Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings